dr. seeds bpc-157 New Office Hours are live!, tackles Bell’s palsy, safety, fibromyalgia support, and immune neuropathy protocols — now in your SSRP Video Vault. #health #wellness INSTAMED® BPC-157 - Rebuild -

These early indicators help confirm biological activity while hair-specific results develop more slowly

Since tirzepatide already activates the GLP-1 receptor along with the GIP receptor, combining it with semaglutide could overstimulate these pathways

FAQ What does BPC + KPV support

Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7

MIC B12 injections do not address serious weight issues or obesity